<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65974">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246998</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-236-0140</org_study_id>
    <secondary_id>2014-002095-93</secondary_id>
    <nct_id>NCT02246998</nct_id>
  </id_info>
  <brief_title>Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults</brief_title>
  <official_title>A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or Other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF) Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults With eGFR ≥70 mL/Min</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess glomerular function before and during administration of stribild
      (STB; elvitegravir [EVG]/cobicistat [COBI]/emtricitabine [FTC]/tenofovir DF [TDF]) or a
      regimen containing TDF without COBI as ritonavir-boosted atazanavir (ATV/r) plus truvada
      (TVD; FTC/TDF) or atripla (ATR; efavirenz [EFV]/FTC/TDF) compared to a regimen containing
      neither TDF nor COBI as ATV/r plus abacavir/lamivudine (ABC/3TC) via determination of actual
      glomerular filtration rate (aGFR) using iohexol (a probe GFR marker) plasma clearance and
      estimated (calculated) glomerular filtration rate (eGFR). This study will assess tubular
      function before and during administration of stribild, ATV/r plus TVD, or atripla compared
      to a regimen of ATV/r plus ABC/3TC. This study will also evaluate the pharmacokinetics (PK),
      antiviral activity, efficacy, safety, and tolerability of the three treatment regimens
      through 24 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual glomerular filtration rate (aGFR) using iohexol plasma clearance (CLiohexol) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated GFR calculated by Cockcroft-Gault formula at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated GFR calculated by Modification of Diet in Renal Disease (MDRD) formula at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal biomarkers of tubular function</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Selected renal biomarkers, including urine glucose (along with serum glucose), urine albumin to creatinine ratio, urine protein to creatinine ratio, urine β2-microglobulin to creatinine ratio, and urine retinal binding protein (RBP) to creatinine ratio will be summarized by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profiles of COBI, RTV, TFV, and iohexol</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>This endpoint will measure the plasma PK profiles of COBI, RTV, tenofovir (TFV), and iohexol.
The following parameters will be measured for COBI, RTV, and TFV, where applicable:
Cmax: maximum observed concentration of drug in plasma
Tmax: time of Cmax
Clast: last observable concentration of drug
Tlast: time of Clast
Ctau: observed drug concentration at the end of the dosing interval
λz: terminal elimination rate constant
AUCtau: concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)
t1/2: estimate of the terminal elimination half-life of the drug
The following parameter will be measured for iohexol, where applicable:
AUCinf: concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cluster of differentiation 4 positive (CD4+) cell count at Week 24</measure>
    <time_frame>Baseline; Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events and laboratory abnormalities</measure>
    <time_frame>Up to 24 weeks plus 30 days</time_frame>
    <description>Incidences of adverse events and laboratory abnormalities will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>STB+iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive STB+iohexol for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RTV+ATV+TVD+iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATR+iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ATR+iohexol for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RTV+ATV+ABC/3TC+iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STB</intervention_name>
    <description>Stribild (STB; EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food</description>
    <arm_group_label>STB+iohexol</arm_group_label>
    <other_name>Stribild®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TVD</intervention_name>
    <description>Truvada (TVD; FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food</description>
    <arm_group_label>RTV+ATV+TVD+iohexol</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR</intervention_name>
    <description>Atripla (ATR; EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily on an empty stomach at bedtime</description>
    <arm_group_label>ATR+iohexol</arm_group_label>
    <other_name>Atripla®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>Ritonavir (RTV) 100 mg tablet administered orally once daily with food</description>
    <arm_group_label>RTV+ATV+TVD+iohexol</arm_group_label>
    <arm_group_label>RTV+ATV+ABC/3TC+iohexol</arm_group_label>
    <other_name>Norvir®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>Atazanavir (ATV) 300 mg capsule administered orally once daily with food</description>
    <arm_group_label>RTV+ATV+TVD+iohexol</arm_group_label>
    <arm_group_label>RTV+ATV+ABC/3TC+iohexol</arm_group_label>
    <other_name>Reyataz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC/3TC</intervention_name>
    <description>Abacavir/Lamivudine (ABC 600 mg/3TC 300 mg) tablet administered orally once daily with food</description>
    <arm_group_label>RTV+ATV+ABC/3TC+iohexol</arm_group_label>
    <other_name>Kivexa®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Iohexol 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24</description>
    <arm_group_label>STB+iohexol</arm_group_label>
    <arm_group_label>RTV+ATV+TVD+iohexol</arm_group_label>
    <arm_group_label>ATR+iohexol</arm_group_label>
    <arm_group_label>RTV+ATV+ABC/3TC+iohexol</arm_group_label>
    <other_name>Omnipaque™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve

          -  Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at Screening

          -  CD4 cell count &gt; 200 cells/µL

          -  Screening genotype report provided by the site must show sensitivity to FTC, TDF,
             EFV, ABC, 3TC, ATV and absence of study drug resistance mutations that include K65R,
             K70E and M184V in RT

          -  Estimated GFR ≥ 70 mL/min

          -  Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase
             [ALT]) ≤ 5 × upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 mg/dL (≤ 26 umol/L), or normal direct bilirubin

          -  Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm^3; platelets ≥
             50,000/mm^3; hemoglobin ≥ 8.5 g/dL)

          -  Serum amylase ≤ 5 × ULN (individuals with serum amylase &gt; 5 × ULN will remain
             eligible if serum lipase is ≤ 5 × ULN)

          -  Normal electrocardiogram (ECG) or not clinically significant if abnormal ECG

          -  Not pregnant or non-lactating females of non-childbearing potential. Or females with
             childbearing potential who agree to utilize highly effective contraception methods or
             be non-heterosexually active or practice sexual abstinence from screening throughout
             the duration of study treatment and for 90 days if taking EFV/FTC/TDF or for 30 days
             for all other study drugs following the last study drug dose

          -  Males who agree to utilize a highly effective method of contraception during
             heterosexual intercourse or be non-heterosexually active, or practice sexual
             abstinence from first dose throughout the study period and for 90 days if taking
             EFV/FTC/TDF or for 30 days for all other study drugs following the last study drug
             dose. Males who agree to refrain from sperm donation from first dose until at least
             90 days if taking EFV/FTC/TDF or for 30 days for all other study drugs following the
             last study drug dose

          -  Body mass index (BMI) of 19 ≤ BMI ≤ 30 kg/m^2 and body weight ≥ 40 kg

          -  Life expectancy ≥ 1 year

        Exclusion Criteria:

          -  HLA-B*5701 allele positive

          -  A new AIDS-defining condition diagnosed within the 30 days prior to screening

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Hepatitis C virus (HCV) antibody positive and HCV RNA detectable

          -  Individuals experiencing decompensated cirrhosis

          -  Females who are breastfeeding

          -  Positive serum pregnancy test

          -  Have an implanted defibrillator or pacemaker

          -  Current alcohol or substance that could potentially interfere with study compliance

          -  A history of malignancy within the past 5 years (prior to screening) or ongoing
             malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
             resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS
             are eligible, but must not have received any systemic therapy for KS within 30 days
             of Day 1 Visit and must not be anticipated to require systemic therapy during the
             study

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Day 1 Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall Fordyce, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 16, 2016</lastchanged_date>
  <firstreceived_date>September 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
